Immune-related adverse events
| Immune-related adverse events | Patients (N, %) |
|---|---|
| Leads to treatment delay | 5 (4.1) |
| Leads to treatment discontinuation | 1 (0.8) |
| Fatal irAEs | 0 (0) |
| Grade 1 total bilirubin increase | 2 (1.6) |
| Grade 1 itching | 1(0.8) |
| Grade 3 nephritis | 1 (0.8) |
| Grade 2 hypothyroidism | 3 (2.5) |
| Grade 2 ALT/AST increase | 4 (3.3) |
| Grade 3 ALT/AST increase | 1 (0.8) |
| Grade 2 skin rash | 2 (1.6) |
| Grade 2 asthenia | 5 (4.1) |
| Grade 2 colitis | 1 (0.8) |
| Grade 2 diarrhea | 1 (0.8) |
| Grade 3 arthritis | 1 (0.8) |
irAEs: immune-related adverse events; ALT: alanine transaminase; AST: aspartate transaminase